NFKB1 and myeloid sarcoma: We will also advance an opinion on how anti-NF-kB, anti-miRNA and/or related therapeutic strategies may be beneficial in the clinical management of MS and other progressive CNS diseases exhibiting inflammatory neurodegeneration.